AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
AIkido Pharma Inc. (Nasdaq: AIKI) announced on July 31, 2020, that it has regained compliance with the NASDAQ's minimum bid price requirement of $1.00. The company met this requirement by maintaining a closing bid price of at least $1.00 for ten consecutive business days. This development supports AIkido's continued presence on the NASDAQ Capital Market, important for its operational stability and investor confidence.
- Regained compliance with NASDAQ's minimum bid price requirement of $1.00, supporting continued listing.
- Closing bid price remained at or above $1.00 for ten consecutive business days.
- None.
NEW YORK, Aug. 3, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on July 31, 2020, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the
About AIkido
AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
| |
Investor Relations: | Hayden IR |
Brett Maas, Managing Partner | |
Phone: (646) 536-7331 | |
Email: brett@haydenir.com | |
AIkido: | Phone: 212-745-1373 |
Email: investorrelations@AIkido.com | |
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-301104540.html
SOURCE AIkido Pharma Inc.
FAQ
What did AIkido Pharma announce on July 31, 2020?
What is the significance of AIkido Pharma's compliance with NASDAQ requirements?
What is the stock symbol for AIkido Pharma?
